

Advancing Innovation and Convergence In Cancer Research

Jerry S.H. Lee, Ph.D.

Deputy Director


Center for Strategic Scientific Initiatives (CSSI)
Office of the Director, National Cancer Institute, NIH

E Kamakani Noi'i: Wind that Seeks Knowledge
Waikiki, Hawai'i

January 14th, 2011

What is It?

Tumor, Cancer, and Metastasis




Site	All stages	Local	Regional	Distant
Breast (female)	86.6	97.0	78.7	23.3
Colon and rectum	62.3	90.1	65.5	9.2
Liver	6.9	16.3	6.0	1.9
Lung and bronchus	14.9	48.7	16.0	2.1
Melanoma	89.6	96.7	60.1	13.8
Ovary	53.0	94.7	72.0	30.7
Pancreas	4.4	16.6	6.8	1.6
Prostate	97.5	100.0	--	34.0
Testis	95.5	99.1	95.0	73.1

“...>90% of deaths is caused by disseminated disease or metastasis...”


Reality: In the U.S., Cancer Continues to be Represent an Enormous Burden

- **569,490** Americans died of cancer in 2010
- **1,529,560** Americans will be diagnosed with cancer this year
- **\$228.1 billion** in 2008 for cancer healthcare costs




Source for 2010 deaths and diagnoses: American Cancer Society (ACS) 2010 Cancer Facts & Figures; Atlanta, Georgia
Source for 2008 age-adjusted death rate: National Center for Health Statistics, NCHS Public-use file for 2008 deaths.

Reality: Global Burden- By 2020, Cancer Mortality 10 M/yr (Incidence 16 M/yr)




Unprecedented Amount of Scientific Knowledge: Omics(ssss)



Is More Knowledge Yielding More Solutions for Patients?


Drugs



Start to Finish

- 10 – 15 years (1,000 – 6,000 volunteers)
- ~ \$1 billion


Diagnostic Biomarkers



- Averaging 1.5 FDA approved per year
- 1000's of samples

Maybe...but can it be more efficient?

Translation Pace: How To Break Out of Current Paradigm?



Katie R. E.

Key Needs (from community)


- Standards and protocols
- Real-time, public release of data
- Multi-disciplinary teams and environment
- Team members with multi-disciplinary **training**

Turning the Crank...

The potential to transform cancer drug discovery and diagnostics

National Cancer Program: Stakeholders

~\$18 B per year



NCI Center for Strategic Scientific Initiatives (CSSI): Concept Shop



Acting Director
Douglas Lowy, MD



Deputy Director
Jerry S.H. Lee, PhD



Mission

“...to create and uniquely implement exploratory programs focused on the development and integration of advanced technologies, trans-disciplinary approaches, infrastructures, and standards, to accelerate the creation and broad deployment of data, knowledge, and tools to empower the entire cancer research continuum in better understanding and leveraging knowledge of the cancer biology space for patient benefit...”

Good Idea + Unique Good Idea Implementation



Innovation




Potential



First Step: Cancer & Genes- Take a Page from Engineers?

Disease of Genomic Alterations

- Copy number
- Expression (regulation of)
- Regulation of translation
- Mutations
- Epigenome



- Systematic identification of all genomic changes
- Repeat for all cancers
- Make it publically available

Saturated steam				Superheated steam		
Pressure (kg/cm ²)	Temp (°C)	Vapour enthalpy (kcal/kg)	Specific volume (m ³ /kg)	Density (kg/m ³)	Specific volume (m ³ /kg)	
					at 250°C	at 300°C
1	99.1	638.8	1.725	0.580	2.454	2.691
2	119.6	646.2	0.902	1.109	1.223	1.342
3	132.9	650.6	0.617	1.621	0.812	0.893
4	142.9	653.7	0.471	2.123	0.607	0.668
5	151.1	656.0	0.382	2.618	0.484	0.533
6	158.1	657.0	0.321	3.115	0.402	0.443
7	164.2	659.5	0.278	3.597	0.343	0.379
8	169.6	660.8	0.245	4.082	0.299	0.331
9	174.5	661.9	0.219	4.566	0.265	0.293
10	179.1	662.9	0.198	5.051	0.238	0.263
12	187.1	664.5	0.166	6.024	0.196	0.218
14	194.1	665.7	0.143	6.993	0.167	0.186
16	200.4	666.7	0.126	7.937	0.145	0.162
18	206.1	667.4	0.112	8.929	0.128	0.143
20	211.4	668.0	0.101	9.901	0.114	0.128
22	216.2	668.4	0.092	10.870	0.103	0.116
24	220.7	668.7	0.085	11.765	0.093	0.106
26	225.0	669.0	0.078	12.821	0.085	0.097
28	229.0	669.1	0.073	13.699	0.078	0.089
30	232.7	669.2	0.068	14.706	0.072	0.083

TCGA: Connecting Multiple Sources, Experiments, and Data Types


THE CANCER GENOME ATLAS




Three Cancers- Pilot

Multiple data types


glioblastoma multiforme
(brain)



squamous carcinoma
(lung)



serous
cystadenocarcinoma
(ovarian)




Biospecimen Core
Resource with more
than 13 Tissue
Source Sites

7 Cancer Genomic
Characterization
Centers

3 Genome
Sequencing
Centers

Data Coordinating
Center

- Clinical diagnosis
- Treatment history
- Histologic diagnosis
- Pathologic status
- Tissue anatomic site
- Surgical history
- Gene expression
- Chromosomal copy number
- Loss of heterozygosity
- Methylation patterns
- miRNA expression
- DNA sequence



Unanticipated Innovation: Cancer Human Biobank (caHUB)


Genomics

Proteomics



All Depend On High-Quality,
Annotated Human Biospecimens

“Garbage In...Garbage Out”



GBM: 400 cases, Lung squamous: 113 cases, Serous ovarian : 486 cases

Unanticipated Innovations...

Mid- 2008


- Reference cancer genome for GBM
- Single author paper (TCGA Network)
 - 300+ authors
- Unanticipated Scientific Discoveries
 - Hypothesis on a possible resistance mechanism to temozolomide (TMZ)

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

The Cancer Genome Atlas Research Network*



2009

- Gene expression-based classification of GBM
- Response to aggressive therapy differs by subtype- **exclude non-responders**



2010


- Identification of new subset of GBM
- Occurs in younger patients
- Evidence of **better prediction of outcomes**



Could We Do the Same for Cancer Proteomics: Not Yet...

THE NATIONAL ACADEMIES
Advisers to the Nation on Science, Engineering, and Medicine

Technologies for Quantitative Analysis



Major Challenges

- Analytical variability in platforms
- Lack of standards, protocols, and reference data
- No consensus on data acquisition, analysis, and open access reporting of raw data


Unlike genomic technologies, proteomic technologies were not yet fully mature

Clinical Proteomic Technologies for Cancer (CPTAC) Pilot



**nature
biotechnology**

Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma



Accomplishments (Highlights)


- First demonstration that MRM is highly reproducible across multiple laboratories and technology platforms
- Development of public data portal of raw mass spec data

Unanticipated Innovations

- Joint development with FDA of mock 510(k) presubmission for proteomic platforms
 - Educate new generation of developers
- Established Antibody Characterization Laboratory
 - Provides high quality reagents at minimum cost to community
 - All characterization data posted on public database
 - Industry partners and collaborations



Full Steam Ahead: CPTC Phase 2 Pipeline (Summer '11)



Now What? How to Interpret It All? (Who?)

LOTS of *Quantitative and Reproducible* Data


Saturated steam				Superheated steam	
Pressure (kg/cm ²)	Temp (°C)	Vapour enthalpy (kcal/kg)	Specific volume (m ³ /kg)	Density (kg/m ³)	Specific volume (m ³ /kg) at 250°C at 300°C
1	99.1	638.8	1.725	0.580	2.454 2.691
2	119.6	646.2	0.902	1.109	1.223 1.342
3	132.9	650.6	0.617	1.621	0.812 0.893
4	142.9	653.7	0.471	2.123	0.607 0.668
5	151.1	656.0	0.382	2.618	0.484 0.533
6	158.1	657.0	0.321	3.115	0.402 0.443
7	164.2	659.5	0.278	3.597	0.343 0.379
8	169.6	660.8	0.245	4.082	0.299 0.331
9	174.5	661.9	0.219	4.566	0.265 0.293
10	179.1	662.9	0.198	5.051	0.238 0.263
12	187.1	664.5	0.166	6.024	0.196 0.218
14	194.1	665.7	0.143	6.993	0.167 0.186
16	200.4	666.7	0.126	7.937	0.145 0.162
18	206.1	667.4	0.112	8.929	0.128 0.143
20	211.4	668.0	0.101	9.901	0.114 0.128
22	216.2	668.4	0.092	10.870	0.103 0.116
24	220.7	668.7	0.085	11.765	0.093 0.106
26	225.0	669.0	0.078	12.821	0.085 0.097
28	229.0	669.1	0.073	13.699	0.078 0.089
30	232.7	669.2	0.068	14.706	0.072 0.083

Harness Understanding

“Simple”



“Complex”



Bringing In New Perspectives: Brainstorming with Experts



~300 extramural participants



Consensus Scientific Themes

- Understanding the Physics of Cancer
- Evolution and Evolutionary Theory in Cancer
- Coding, Decoding and Transfer of Information in Cancer
- “De-convoluting” the Complexity of Cancer


Consensus Needs

- Establish trans-disciplinary physical sciences-oncology centers
- Centers composed of integrated physical sciences-oncology teams
- Focus on theme(s) for center framework
- Centers led by physical scientists with co-investigator(s) from cancer biology/oncology


Critical to Think in Terms of Space and Time





Metastasis: Rare, Random, Deleterious



Well-known to
be an inefficient
process (0.01%)





Physical Sciences-Oncology Centers Program Goal and Vision



- To generate **new knowledge** and catalyze **new fields of study** in cancer research by utilizing physical sciences/engineering principles to enable a better understanding of cancer and its behavior at all scales.
- Not looking for new tools to do “better” science, but new perspectives and approaches to do **paradigm-shifting** science that will lead to exponential progress against cancer.
- Build **trans-disciplinary teams** and infrastructure to better understand and control cancer through the convergence of physical sciences and cancer biology.



New – “Schools of Thought”


Physical Sciences-Oncology Centers (PS-OC) Network

Physics of Cancer

Information Coding,
Decoding, Transfer, and
Translation in Cancer


Evolution and Evolutionary
Theory of Cancer

De-convoluting Cancer's
Complexity



A Future Where Personalized Medicine Becomes Reality

Individualized, Targeted Cancer Care



Learn More About CSSI...



A screenshot of the CSSI website homepage. The top navigation bar is red with the "National Cancer Institute" logo and name on the left, and "U.S. National Institutes of Health | www.cancer.gov" on the right. Below this is a grey header with the CSSI logo and name on the left, and a navigation menu with links: "HOME", "ABOUT CSSI", "CSSI OFFICES", and "CONTACT CSSI". The main content area has a dark background with a large, colorful DNA double helix graphic on the right. The text on the left reads: "ENABLING PROGRESS IN CANCER RESEARCH THROUGH ADVANCED TECHNOLOGIES, TRANS-DISCIPLINARY PROGRAMS AND RESOURCES". Below this text is a "LEARN MORE" link with a right-pointing arrow. At the bottom, there is a footer with links: "NCI Home", "CSSI Home", "Contact Us", "Policies", "Accessibility", "Viewing Files", and "FOIA". Below these links is the text "A Service of the National Cancer Institute". At the very bottom, there are logos for the National Cancer Institute, the U.S. Department of Health and Human Services, and the USA.GOV logo.

<http://cssi.cancer.gov>

